510(k) Report

FDA product code · Clinical chemistry

Acid, Folic, Radioimmunoassay

CGNClass II21 CFR 862.1295510(k) required64 decisions since 197629 recalls

64 FDA decisions since 1976. 510(k) reviews decided 2021–2025 took a median of 266 days (half between 265 and 266). 29 recalls name this code, 0 of them Class I. The most-cited predicate is K935286, named by 5 later devices.

Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly, last Nov 3, 2026 Download the data (CSV)

FIG. A — Illustration, clinical chemistry panel

Twenty years of CGN at a glance: how often FDA decides these devices, how long 510(k) reviews take, how often they are recalled, and how many adverse event reports name the code.

FDA decisions per year · CGN

1in 2024

2009: 22010: 12011: 12014: 12016: 12018: 12020: 12023: 12024: 1
2007high 2 (2009) · low 0 (2007)2026

2026 to Oct 25, outlined.

Median 510(k) review, days · CGN

Too few CGN 510(k)s in any year since 2007 to give a median.

Recalls per year · CGN

3in 2019

2007: 22008: 12009: 12010: 12012: 22013: 12018: 22019: 3
2007high 3 (2019) · low 0 (2011)2026

Class I (0 since 2007) Class II/III not classified

Adverse event reports per year · CGN

9in 2025

2007: 262009: 32011: 282012: 112013: 22014: 42015: 12016: 42017: 62018: 22019: 12020: 52021: 32022: 132023: 82024: 192025: 9
2007high 28 (2011) · low 0 (2008)2025

MAUDE reports naming product code CGN, not matched to any one device; reports are not rates.

View these four charts as a table
YearDecisionsMedian 510(k) review, daysRecalls (Class I)MAUDE reports
20070—226
20080—10
20092—13
20101—10
20111—028
20120—211
20130—12
20141—04
20150—01
20161—04
20170—06
20181—22
20190—31
20201—05
20210—03
20220—013
20231—08
20241—019
20250—09
20260—0—
FIG. 1 — CGN by year, 2007–2026Sources: FDA decision databases, recall and enforcement reports, MAUDE · Data through Oct 25, 2026

Planning a device in CGN? A 510(k) Report ranks candidate predicates in this code by lineage, citations and recall history, with the review-time outlook.

See the 510(k) Report